The DOI matches its Crossref record; 244 of the 254 references it cites were found in a registry or an index; 39 of the 166 sources its claims cite were checked for support.
Novel therapeutic targets for cholestatic and fatty liver disease
Open accessAbstract
Cholestatic and non-alcoholic fatty liver disease (NAFLD) share several key pathophysiological mechanisms which can be targeted by novel therapeutic concepts that are currently developed for both areas. Nuclear receptors (NRs) are ligand-activated transcriptional regulators of key metabolic processes including hepatic lipid and glucose metabolism, energy expenditure and bile acid (BA) homoeostasis, as well as inflammation, fibrosis and cellular proliferation. Dysregulation of these processes contributes to the pathogenesis and progression of cholestatic as well as fatty liver disease, placing NRs at the forefront of novel therapeutic approaches. This includes BA and fatty acid activated NRs such as farnesoid-X receptor (FXR) and peroxisome proliferator-activated receptors, respectively, for which high affinity therapeutic ligands targeting specific or multiple isoforms have been developed. Moreover, novel liver-specific ligands for thyroid hormone receptor beta 1 complete the spectrum of currently available NR-targeted drugs. Apart from FXR ligands, BA signalling can be targeted by mimetics of FXR-activated fibroblast growth factor 19, modulation of their enterohepatic circulation through uptake inhibitors in hepatocytes and enterocytes, as well as novel BA derivatives undergoing cholehepatic shunting (instead of enterohepatic circulation). Other therapeutic approaches more directly target inflammation and/or fibrosis as critical events of disease progression. Combination strategies synergistically targeting metabolic disturbances, inflammation and fibrosis may be ultimately necessary for successful treatment of these complex and multifactorial disorders.
Overview
CoChat Summary
TL;DR
This review argues that cholestatic and non-alcoholic fatty liver disease share key pathophysiological mechanisms and that nuclear receptors and bile acid signalling are leading therapeutic targets. It summarizes phase 2/3 trial data for FXR, PPAR, FGF19/21, THR-β1, norUDCA, CCR2/5, and LOXL2-directed agents, concluding that combination strategies may ultimately be necessary.
Key findings
- Cholestasis and NAFLD/NASH converge on substrate overload, cell stress, inflammation, and fibrosis; nuclear receptors are broadly expressed in hepatocytes, cholangiocytes, hepatic stellate cells, and immune cells, making them attractive targets.
- FXR/BA-directed therapies show mixed results: in PBC, obeticholic acid improved biochemical markers and was conditionally approved as second-line therapy; in NASH, FLINT reported improved NAFLD activity score but NASH resolution of 22% vs 13% with placebo, while fibrosis improved in 35% vs 19%; REGENERATE interim analysis showed fibrosis improvement >1 stage in 23% vs 12% with placebo but no significant NASH improvement (12% vs 8%).
- PPAR and THR-β1 ligands also show signals: bezafibrate produced complete biochemical response in 31% of PBC patients with incomplete UDCA response vs 0% on placebo, with ALP normalisation in 67%; pioglitazone improved transaminases, steatosis, and inflammation but not fibrosis or NASH in PIVENS; resmetirom reduced hepatic fat and improved histological NAS in phase 2 NASH.
- Other approaches include norUDCA, which improved ALP in phase 2 PSC and reduced ALT in phase 2a NAFLD, while cenicriviroc showed no significant antifibrotic effect at 2 years and the AURORA phase 3 trial was terminated early for lack of efficacy; simtuzumab failed to improve fibrosis in NASH or PSC.
Methods
- Narrative review synthesizing mechanistic literature and clinical trial data across cholestatic liver diseases and NAFLD/NASH.
- Table 1 compiles key clinical trials of steroidal and non-steroidal FXR agonists, FGF19 mimetics, PPAR agonists, FGF21 mimetics, THR-β1 agonists, norUDCA, CCR2/CCR5 antagonists, and LOXL2 inhibitors.
- No systematic search, meta-analysis, or primary data collection is reported.
Limitations
- The paper states that long-term efficacy, tolerability, and safety of novel therapies still need evaluation, and that benefit on “hard” clinical endpoints remains to be demonstrated for OCA in PBC.
- The paper notes challenges such as high malignancy risk in PSC and the need for innovative trial designs such as basket trials.
- Evident from the text: this is a narrative review with selected trial coverage, including interim and ongoing study results, and no quantitative synthesis; later trials published after 2022 are not included.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
24 Valid · 7 Not valid · 83 Not checked · 13 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However, small molecule inhibitors of NTCP can also prevent HBV infection without interrupting BA uptake.204”
§ Novel therapeutic targets for cholestatic and fatty liver disease > Enterohepatic bile acid circulation as therapeutic target
What the sources say
- Disputedcites [204] Kaneko, 2018, Chemical array system, a platform to identify novel hepatitis B virus entry inhibitors targeting sodium taurocholate cotransporting polypeptide, Sci Rep sourceExperimental — accuracy not yet measured
The Results section (“NPD8716 impaired the NTCP-dependent bile acid uptake”; page not available) says NPD8716 reduced NTCP-mediated bile acid uptake in a dose-dependent manner. The derivative analysis also reports that inhibition of HBV entry correlated with impairment of bile acid uptake. Thus, the inhibitors studied here do not support the claim that HBV infection was prevented without interrupting bile acid uptake. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Interestingly, BA toxicity as result of impaired hepatobiliary excretory function18 19 and functional (micro)cholestasis20 may also be involved in the pathogenesis of NASH.12”
§ Novel therapeutic targets for cholestatic and fatty liver disease > Shared pathogenetic principles as targets for therapeutic interventions
What the sources say
- Partly supportedcites [18] Pizarro, 2004, Bile secretory function in the obese Zucker rat: evidence of cholestasis and altered canalicular transport function, Gut sourceExperimental — accuracy not yet measured
Our copy supports the excretory/cholestatic half of the claim: the Abstract and Introduction report that obese Zucker rats exhibit impaired bile secretory function with functional and molecular alterations 'consistent with mild cholestasis' and decreased expression/function of critical canalicular transporters producing 'impaired excretory function of the liver', and that 'a defective hepatobiliary transport capacity may be a contributory factor in rendering the obese ZR more susceptible to liver injury'. However, the Introduction frames the injury mechanism generically — 'substances normally secreted into bile accumulate inside the cell promoting liver injury and leading to both necrosis and apoptosis' — without attributing it specifically to bile acid toxicity, and the term 'microcholestasis' does not appear. The claim's extension to the pathogenesis of NASH also goes beyond what this source states, which concerns susceptibility of a rodent NAFLD model to added insults (endotoxin, ischaemia/reperfusion) rather than steatohepatitis pathogenesis. (LLM, conf=0.72)
- Not checked yetcites [19] Geier, 2005, Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat, J Hepatol source
- Supportedcites [20] Segovia-Miranda, 2019, Three-Dimensional spatially resolved geometrical and functional models of human liver tissue reveal new aspects of NAFLD progression, Nat Med source
The Discussion states exactly this chain: altered bile-canalicular microanatomy and the consequent pericentral micro-cholestasis 'may hamper BAs secretion into BC' (impaired hepatobiliary excretory function), bile accumulation 'due to its detergent-like properties, can cause liver damage', and BA accumulation 'could induce oxidative stress and trigger apoptosis', consistent with loss of pericentral hepatocytes in STEA and eNASH. The same Discussion section (and continuation) frames pericentral micro-cholestasis as 'a new piece in the NAFLD pathophysiology puzzle', while Results (Personalised model of bile flow...) and its Discussion supply the supporting prediction of elevated pericentral bile pressure with raised serum GGT and primary BAs in eNASH. The hedged wording of the claim ('may also be involved') matches the source's own hedging ('may hamper', 'could induce', 'suggests'). (LLM, conf=0.85)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“while cholestasis may be considered an efflux problem resulting in accumulation of potentially cytotoxic and proinflammatory BAs and other cholephiles.13 14”
§ Novel therapeutic targets for cholestatic and fatty liver disease > Shared pathogenetic principles as targets for therapeutic interventions
What the sources say
- Not checked yetcites [13] Trauner, 2017, New therapeutic concepts in bile acid transport and signaling for management of cholestasis, Hepatology source
- Supportedcites [14] Jansen, 2017, The ascending pathophysiology of cholestatic liver disease, Hepatology source
Our copy treats cholestasis in exactly these terms: the TOXICITY OF BS section states that bile salts at accumulating concentrations 'may cause apoptosis, at 200 [µM] they activate proinflammatory genes, at 200-2,000 [µM] they induce necrosis' and refers to 'the inherent cytotoxicity of BS', and describes hepatocytes/cholangiocytes being 'exposed to toxic BS concentrations'. The ADAPTATION OF HEPATOCYTES section supplies the efflux framing, noting that canalicular Bsep/BSEP and Mrp2/MRP2 'helps to remove bile acids and other toxic agents from hepatocytes' (i.e. bile acids plus other transported substrates, the 'cholephiles' of the claim) and that cells which 'fail to exclude BS' accumulate them (Fig. 3C, 'accumulation in individual sporadic hepatocytes'). The wording 'efflux problem' and 'cholephiles' is the citing authors' shorthand, but the content — impaired biliary export with build-up of cytotoxic and proinflammatory bile acids and other transported agents — is what our copy states, with the same hedging level. (LLM, conf=0.82)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“NASH may therefore be grossly viewed as an influx problem due to increased fatty acid load with consecutive lipotoxicity,11 12”
§ Novel therapeutic targets for cholestatic and fatty liver disease > Shared pathogenetic principles as targets for therapeutic interventions
What the sources say
- Supportedcites [11] Neuschwander-Tetri, 2010, Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites, Hepatology source
The “Factors Predisposing to Production of Lipotoxic Intermediates and NASH” section says that excessive fatty-acid delivery or synthesis contributes to NASH. It also explains that increased supply may be harmless if disposal pathways are robust, consistent with the claim’s qualified, broad framing. Page numbers are unavailable in our copy. (LLM, conf=0.90)
- Partly supportedcites [12] Arab, 2017, Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives, Hepatology sourceExperimental — accuracy not yet measured
The section “Bile Acids and FXR: Regulation of Glucose and Lipid Metabolism” links fatty-acid metabolism to hepatic lipid accumulation, and “TGR5 Agonism and TGR5/FXR Dual Agonists” discusses reduced lipotoxicity in connection with NASH treatment. Neither passage characterizes NASH as primarily an influx problem caused by an increased fatty-acid load, so that part of the paraphrase is unsupported. (LLM, conf=0.78)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“BA-induced cell stress may occur both at the level of hepatocytes (eg, via BA retention) and cholangiocytes (eg, via toxic bile composition and/or biliary stasis).5 14”
§ Novel therapeutic targets for cholestatic and fatty liver disease > Shared pathogenetic principles as targets for therapeutic interventions
What the sources say
- Supportedcites [5] Hirschfield, 2010, Pathogenesis of cholestatic liver disease and therapeutic approaches, Gastroenterology source
The source states bile-acid injury at both cell types: the Inherited Cholestatic Syndromes section describes 'decreased biliary bile salt secretion, decreased bile flow, and hepatic accumulation of bile acids' (i.e. hepatocyte retention) with bile 'especially toxic to the canalicular membrane', and loss of phosphatidylcholine protection exposing 'the bile duct epithelium from the detergent properties of bile acids' (i.e. cholangiocyte stress from toxic bile composition/stasis). The Abstract and Figure 1 legend frame cholestatic pathogenesis as 'the responses of cholangiocytes and hepatocytes to injury' with 'accumulation of bile and liver tissue damage'. The citing sentence is hedged ('may occur') and adds no mechanism beyond what the review reports, so no qualifier is overstated. (LLM, conf=0.85)
- Supportedcites [14] Jansen, 2017, The ascending pathophysiology of cholestatic liver disease, Hepatology source
The TOXICITY OF BS section states that after a breach of the bile-blood barrier 'the periductular stroma and the basolateral plasma membrane domains of hepatocytes and cholangiocytes are exposed to toxic BS concentrations,' adding toxic damage to immune-mediated injury — i.e. BA/BS-induced stress at both cell levels. The ADAPTATION OF HEPATOCYTES section supports the hepatocyte side with retention ('a small number of individual cells that fail to exclude BS... enrichment seems to occur through the apical membrane... associated with subsequent cell death... a bile infarct of the size of a single hepatocyte'), and the biliary-tree/intraluminal-pressure passages support cholangiocyte-level stress from stasis/pressure and BS reabsorption by cholangiocytes. The claim's hedge ('may') matches the paper's own tentative framing, so nothing attributed here exceeds the source. (LLM, conf=0.82)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
60 more claims · 11 with their cited sources checked
Create a free account to see all 127 claims and to verify the 127 references still open.
- It may state two separate claims as one. 56
- Probably not a substantial claim. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, several drugs known to affect bile homeostasis also improve liver blood tests, 13,14 suggesting an involvement of these systems in PSC development.”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Novel therapeutic targets for cholestatic and fatty liver disease > Nuclear receptor pathways as a new therapeutic frontier > Farnesoid X receptor
“In line with the beneficial effects of OCA in PBC, encouraging results were also observed in patients with PSC97 (table 1).”
§ Novel therapeutic targets for cholestatic and fatty liver disease > References
“97. Bowlus CL, Pockros PJ, Kremer AE, et al. Long-Term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Novel therapeutic targets for cholestatic and fatty liver disease > Nuclear receptor pathways as a new therapeutic frontier
“ALP, alkaline phosphatase; ALT, alkaline phosphatase”
§ Novel therapeutic targets for cholestatic and fatty liver disease > Nuclear receptor pathways as a new therapeutic frontier > Farnesoid X receptor
“alanine amino transferase (ALT)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Novel therapeutic targets for cholestatic and fatty liver disease > Enterohepatic bile acid circulation as therapeutic target
“genetic absence of NTCP in mice and men results in increased serum levels of unconjugated BAs”
§ Novel therapeutic targets for cholestatic and fatty liver disease > References
“Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype.”
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Vrieze, A., Van Nood, E., Holleman, F., Salojärvi, J., Kootte, R. S., Bartelsman, J. F. W. M., Dallinga–Thie, G. M., Ackermans, M. T., Serlie, M. J., Oozeer, R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.031 · Cited by 2,913
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Bile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829
Identification of a nuclear receptor for bile acids
Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714
Research works printed but not linked: 6
- Kowdley, 2019, The nonsteroidal farnesoid X receptor (FXR) agonist Cilofexor improves liver biochemistry in patients with primary biliary cholangitis (pBC): a phase 2, randomized, placebo-controlled trial, Hepatology, 70, 31a
- Alkhouri, 2020, Safety and efficacy of combination therapies including Semaglutide, Cilofexor, and Firsocostat in patients with NASH, Hepatology, 72, 131A
- Lucas, 2020, Safety and efficacy of tropifexor in patients with fibrotic nonalcoholic steatohepatitis: 48‐week results from part C of the phase 2 flight‐fxr study, Hepatology, 72, 101A
- Harrison, 2020, A 52-week multi-center double-blind randomized phase 2 study of Seladelpar, a potent and selective peroxisome proliferator-activated receptor delta (PPAR-delta) agonist, in patients with nonalcoholic steatohepatitis (NASH), Hepatology, 72, 1043A
- Harrison, 2020, RESOLVE-IT phase 3 of Elafibranor in NASH: final results of the week 72 interim surrogate efficacy analysis, Hepatology, 72, LP23
- Harrison, 2021, Efruxifermin (EFX) improved markers of fibrosis, liver injury andmetabolism in F4 NASH patients with compensated cirrhosis, J Hepatol, 75
Cited by
Peiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.012 · Cited by 564
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Self-citationWhat defines a healthy gut microbiome?
Van Hul, M., Cani, P. D., Petitfils, C., De Vos, W. M., Tilg, H., & El-Omar, E. M. (2024) · Gut · doi:10.1136/gutjnl-2024-333378 · Cited by 369
Current treatment of non‐alcoholic fatty liver disease
Paternostro, R., & Trauner, M. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13531 · Cited by 305
Self-citationBile acid metabolism and signalling in liver disease
Fuchs, C. D., Simbrunner, B., Baumgartner, M., Campbell, C., Reiberger, T., & Trauner, M. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.09.032 · Cited by 231
Self-citation
Metadata
- Authors
- Trauner, M., & Fuchs, C. D.
- Affiliations
- Medical University of Vienna (AT)
- Corresponding author
- Trauner, Michael
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2021-10-06
- Volume
- 71
- Issue
- 1
- Pages
- 194-209
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- PMC
- PMC8666813
- OpenAlex
- W3204219369
- Cited by
- 204
- References
- 254
- Citations by year
- 2026: 38 · 2025: 42 · 2024: 44 · 2023: 48 · 2022: 32
- FWCI
- 4.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Gut (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Austrian Science Fund (F7310‐B21, I2755-B30)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- cholestatic liver disease, non-alcoholic fatty liver disease, nuclear receptors, farnesoid X receptor, peroxisome proliferator-activated receptors, thyroid hormone receptor beta 1, bile acid signaling, FGF19, enterohepatic circulation, liver fibrosis, liver inflammation, hepatic lipid metabolism
- MeSH terms
- Cholestasis, Gastrointestinal Agents, Humans, Receptors, Cytoplasmic and Nuclear, Molecular Targeted Therapy, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel therapeutic targets for cholestatic and fatty liver disease. https://app.cochat.ai/papers/10.1136/gutjnl-2021-324305
- The paper
- Trauner, M., & Fuchs, C. D. (2022). Novel therapeutic targets for cholestatic and fatty liver disease. Gut. https://doi.org/10.1136/gutjnl-2021-324305
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.